{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:47:36Z","timestamp":1770223656643,"version":"3.49.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.neuropharm.2018.05.001","type":"journal-article","created":{"date-parts":[[2018,5,5]],"date-time":"2018-05-05T09:08:40Z","timestamp":1525511320000},"page":"96-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["5-HT1A receptor stimulation in the medial prefrontal cortex mediates the antidepressant effects of mGlu2\/3 receptor antagonist in mice"],"prefix":"10.1016","volume":"137","author":[{"given":"Kenichi","family":"Fukumoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiko","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Funakoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeyuki","family":"Chaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2018.05.001_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.neuropharm.2012.09.008","article-title":"Metabotropic glutamate 2\/3 receptor antagonists improve behavioral and prefrontal dopaminergic alterations in the chronic corticosterone-induced depression model in mice","volume":"65","author":"Ago","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.05.001_bib2","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1017\/S1461145709991222","article-title":"F15599, a highly selective post-synaptic 5-HT(1A) receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity","volume":"13","author":"Assi\u00e9","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.001_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature10130","article-title":"NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses","volume":"475","author":"Autry","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2018.05.001_bib4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.05.001_bib5","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1046\/j.1471-4159.2000.0750889.x","article-title":"Regulation of neurotransmitter release by metabotropic glutamate receptors","volume":"75","author":"Cartmell","year":"2000","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2018.05.001_bib6","doi-asserted-by":"crossref","first-page":"9917","DOI":"10.1523\/JNEUROSCI.21-24-09917.2001","article-title":"Control of dorsal raphe serotonergic neurons by the medial prefrontal cortex: involvement of serotonin-1A, GABA(A), and glutamate receptors","volume":"21","author":"Celada","year":"2001","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2018.05.001_bib7","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.tips.2017.03.008","article-title":"mGlu2\/3 receptor antagonists as novel antidepressants","volume":"38","author":"Chaki","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2018.05.001_bib8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.neuropharm.2012.05.022","article-title":"mGlu2\/3 and mGlu5 receptors: potential targets for novel antidepressants","volume":"66","author":"Chaki","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.05.001_bib9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.neuropharm.2003.10.009","article-title":"MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity","volume":"46","author":"Chaki","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.05.001_bib10","first-page":"228","article-title":"Rapid and sustained antidepressant action of the mGlu2\/3 receptor antagonist MGS0039 in the social defeat stress model: comparison with ketamine","volume":"20","author":"Dong","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.001_bib11","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1007\/s00213-016-4327-5","article-title":"Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression","volume":"233","author":"du Jardin","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2018.05.001_bib12","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nm.4050","article-title":"Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants","volume":"22","author":"Duman","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2018.05.001_bib13","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1017\/S1461145711001702","article-title":"mTOR activation is required for the antidepressant effects of mGluR\u2082\/\u2083 blockade","volume":"15","author":"Dwyer","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.001_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/2049-9256-1-15","article-title":"mGluR2\/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure","volume":"1","author":"Dwyer","year":"2013","journal-title":"J.\u00a0Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.05.001_bib15","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1007\/s00213-013-3378-0","volume":"231","author":"Fukumoto","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2018.05.001_bib16","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/npp.2015.233","article-title":"The antidepressant effects of an mGlu2\/3 receptor antagonist and ketamine require AMPA receptor stimulation in the mPFC and subsequent activation of the 5-HT neurons in the DRN","volume":"41","author":"Fukumoto","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.05.001_bib17","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/ijnp\/pyx116","article-title":"Role of 5-HT1A receptor stimulation in the medial prefrontal cortex in the sustained antidepressant effects of ketamine","volume":"21","author":"Fukumoto","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.001_bib18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00213-013-3024-x","article-title":"Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism","volume":"228","author":"Gigliucci","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2018.05.001_bib19","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1038\/sj.bjp.0702510","article-title":"Role of the medial prefrontal cortex in 5-HT1A receptor-induced inhibition of 5-HT neuronal activity in the rat","volume":"126","author":"Haj\u00f3s","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.001_bib20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.tins.2009.11.003","article-title":"mTOR signaling: at the crossroads of plasticity, memory and disease","volume":"33","author":"Hoeffer","year":"2010","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2018.05.001_bib21","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.neubiorev.2008.11.005","article-title":"Stress-induced prefrontal reorganization and executive dysfunction in rodents","volume":"33","author":"Holmes","year":"2009","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2018.05.001_bib22","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.neuroscience.2014.04.046","article-title":"Rivastigmine improves hippocampal neurogenesis and depression-like behaviors via 5-HT1A receptor stimulation in olfactory bulbectomized mice","volume":"272","author":"Islam","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2018.05.001_bib23","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.brainres.2005.02.032","article-title":"AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist","volume":"1042","author":"Karasawa","year":"2005","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2018.05.001_bib24","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.neulet.2004.12.021","article-title":"Neuropharmacological profiles of antagonists of group II metabotropic glutamate receptors","volume":"378","author":"Kawashima","year":"2005","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2018.05.001_bib25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bbr.2014.05.065","article-title":"Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats","volume":"271","author":"Koike","year":"2014","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2018.05.001_bib26","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.neuropharm.2011.08.034","article-title":"Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists","volume":"61","author":"Koike","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.05.001_bib27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bbr.2012.10.023","article-title":"Role of BDNF\/TrkB signaling in antidepressant-like effects of a group II metabotropic glutamate receptor antagonist in animal models of depression","volume":"238","author":"Koike","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2018.05.001_bib28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.pbb.2013.03.017","article-title":"Effects of ketamine and LY341495 on the depressive-like behavior of repeated corticosterone-injected rats","volume":"107","author":"Koike","year":"2013","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2018.05.001_bib29","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2018.05.001_bib30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.biopsych.2007.05.028","article-title":"Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors","volume":"63","author":"Maeng","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.05.001_bib31","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0028-3908(01)00050-8","article-title":"Electrophysiological evidence for postsynaptic 5-HT(1A) receptor control of dorsal raphe 5-HT neurones","volume":"41","author":"Mart\u00edn-Ruiz","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.05.001_bib32","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/jpet.105.091199","article-title":"Ketamine produces lasting disruptions in encoding of sensory stimuli","volume":"316","author":"Maxwell","year":"2006","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2018.05.001_bib33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00429-014-0890-x","article-title":"The peptidic antidepressant spadin interacts with prefrontal 5-HT(4) and mGluR(2) receptors in the control of serotonergic function","volume":"221","author":"Moha ou Maati","year":"2016","journal-title":"Brain Struct. Funct."},{"key":"10.1016\/j.neuropharm.2018.05.001_bib34","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/clpt.2011.244","article-title":"Ketamine as a novel antidepressant: from synapse to behavior","volume":"91","author":"Murrough","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2018.05.001_bib35","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/0896-6273(94)90043-4","article-title":"Metabotropic glutamate receptors: synaptic transmission, modulation, and plasticity","volume":"13","author":"Nakanishi","year":"1994","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2018.05.001_bib36","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1021\/jm970498o","article-title":"2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability","volume":"41","author":"Ornstein","year":"1998","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2018.05.001_bib37","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00213-010-1978-5","article-title":"On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039","volume":"212","author":"Pa\u0142ucha-Poniewiera","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2018.05.001_bib38","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.neuropharm.2016.05.010","article-title":"Ketamine treatment involves medial prefrontal cortex serotonin to induce a rapid antidepressant-like activity in BALB\/cJ mice","volume":"112","author":"Pham","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.05.001_bib39","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.bcp.2007.09.021","article-title":"Mood disorders: regulation by metabotropic glutamate receptors","volume":"75","author":"Pilc","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.001_bib40","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.cellsig.2011.09.009","article-title":"Functional significance of glycogen synthase kinase-3 regulation by serotonin","volume":"24","author":"Polter","year":"2012","journal-title":"Cell Signal"},{"key":"10.1016\/j.neuropharm.2018.05.001_bib41","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/npp.2009.104","article-title":"Neurocircuitry of mood disorders","volume":"35","author":"Price","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.05.001_bib42","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/mol.53.2.228","article-title":"In\u00a0vitro binding characteristics of a new selective group II metabotropic glutamate receptor radioligand, [3H]LY354740, in rat brain","volume":"53","author":"Schaffhauser","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.001_bib43","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0165-6147(93)90107-U","article-title":"Metabotropic glutamate receptors in brain function and pathology","volume":"14","author":"Schoepp","year":"1993","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2018.05.001_bib44","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.neuroscience.2014.11.025","article-title":"Rapid-acting antidepressant-like effects of acetyl-l-carnitine mediated by PI3K\/AKT\/BDNF\/VGF signaling pathway in mice","volume":"285","author":"Wang","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2018.05.001_bib45","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1124\/jpet.116.233627","article-title":"The rapidly acting antidepressant ketamine and the mGlu2\/3 receptor antagonist LY341495 rapidly engage dopaminergic mood circuits","volume":"358","author":"Witkin","year":"2016","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2018.05.001_bib46","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00213-006-0390-7","article-title":"An mGluR2\/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats","volume":"186","author":"Yoshimizu","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2018.05.001_bib47","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A\u00a0randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.05.001_bib48","article-title":"5-Hydroxytryptamine-independent antidepressant actions of (R)-ketamine in a chronic social defeat stress model","author":"Zhang","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818302004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818302004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T13:31:35Z","timestamp":1561210295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390818302004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":48,"alternative-id":["S0028390818302004"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.05.001","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"5-HT1A receptor stimulation in the medial prefrontal cortex mediates the antidepressant effects of mGlu2\/3 receptor antagonist in mice","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}